Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.

about

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.

Item

http://www.wikidata.org/entity/Q48352608

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Postoperative survival of EGFR ...... ations: a retrospective study.

@en

Postoperative survival of EGFR ...... ations: a retrospective study.

@nl

type

Item

label

Postoperative survival of EGFR ...... ations: a retrospective study.

@en

Postoperative survival of EGFR ...... ations: a retrospective study.

@nl

prefLabel

Postoperative survival of EGFR ...... ations: a retrospective study.

@en

Postoperative survival of EGFR ...... ations: a retrospective study.

@nl

P1476

Postoperative survival of EGFR ...... tations: a retrospective study

@en

P2093

Hao Pan

http://www.w3.org/2001/XMLSchema#string

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Shuanghua Xie

http://www.w3.org/2001/XMLSchema#string

Tiejun Liu

http://www.w3.org/2001/XMLSchema#string

Wenjing Yang

http://www.w3.org/2001/XMLSchema#string

Xiaofan Yang

http://www.w3.org/2001/XMLSchema#string

Xiaoli Feng

http://www.w3.org/2001/XMLSchema#string

Xiaoshuang Feng

http://www.w3.org/2001/XMLSchema#string

Xuelian Li

http://www.w3.org/2001/XMLSchema#string

Yonggang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.

Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.

P2888

s12957-017-1251-z

P304

197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12957-017-1251-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yi-Bo Gao

Jie He

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092562934

http://www.w3.org/2001/XMLSchema#string

P698

29110716

http://www.w3.org/2001/XMLSchema#string

P932

5674232

http://www.w3.org/2001/XMLSchema#string